Darnytsia Participated in the Development of a Roadmap for Changes to National Legislation in the Field of Pharmacy
Darnytsia Pharmaceutical Company took part in developing a roadmap for changes to national legislation in the field of pharmacy, aiming to adapt it to EU standards and best practices, and to ensure patients have access to affordable, high-quality, and safe medicines.
The development of the roadmap involved representatives of the authorities, including the Ministry of Health of Ukraine, the Verkhovna Rada Committee on National Health, Medical Care and Health Insurance, the National Academy of Legal Sciences, scientists, lawyers, representatives of patient organizations, and leading pharmaceutical manufacturers in the country.
The result of their work was a resolution providing for the creation of a model of the Ukrainian pharmaceutical market focused on the consumer, the healthcare system, and the best practices of the European Union.
The priorities of this model are:
• Fair prices for medicines, not marketing markups: it is proposed to ban hidden marketing bonuses and ensure transparency in the formation of drug prices.
• A pharmacy is not just a marketplace, but part of the healthcare system: pharmacies should not only be retail outlets, but also part of the healthcare system, where qualified pharmacists provide professional consultations.
• Access to effective medicines—regardless of place of residence or income level: it is necessary to ensure the presence of pharmacies in villages, frontline areas, and near medical institutions, as well as to create mechanisms to control their accessibility.
• New medicines—immediately after patent expiration: it is proposed to introduce mechanisms for rapid access to generic medicines after the expiration of patent protection.
• Social protection—for those who truly need support: expanding state compensation programs for medicines for vulnerable groups such as pensioners, people with chronic illnesses, people with disabilities, and large families.
• Public oversight—a guarantee that the system will no longer operate “in the shadows”: it is necessary to introduce public oversight of the pharmaceutical market, transparent procedures, and open data, which will allow citizens to actively participate in monitoring prices and the availability of medicines.
“As a responsible pharmaceutical manufacturer, Darnytsia sees the need for pharmacy market reform in the interests of patients. Our direction is the EU. Therefore, our market must also be oriented toward European standards. Reforms are never easy. As a manufacturer, we are losing profits today, but we are ready for this. The pharmacy market must have clear rules of the game. In the long run, society will benefit from this, and the interests of the patient will be protected,” said Kostiantyn Vashchenko, Government Relations Director at Darnytsia Pharmaceutical Company.